Answers are grounded in this paper and cite their sources.
Background Prostate cancer progression involves metabolic reprogramming, but whether these changes differ according to ERG status remains unclear. This study aimed to characterize ERG-associated metabolic patterns during progression to metastatic castration-resistant prostate cancer (mCRPC) and to identify and functionally validate genes contributing to these features. Methods ERG-stratified bulk transcriptomic analyses were integrated with single-cell analyses to examine relationships between progression-associated tumor cell states and metabolic programs in ERG-negative prostate cancer and to prioritize candidate genes. Acetyl-CoA acetyltransferase 1 (ACAT1) was depleted in two ERG-negative prostate cancer cell lines, PC3 and C4-2B, to assess progression-related phenotypes and SOX4 protein regulation. Human prostate cancer tissues were examined for spatial relationships between ACAT1 and SOX4. Metabolomic and lipidomic profiling, extracellular lipid restriction, and PPARγ antagonism were used to investigate metabolic remodeling and its functional consequences. Results Integrated transcriptomic analyses revealed progression-associated suppression of metabolic programs in ERG-negative prostate cancer and identified a stemness-associated, epithelial–mesenchymal transition (EMT)-like, androgen receptor (AR)-low tumor cell state with elevated ACAT1 expression. ACAT1 depletion suppressed proliferation, anchorage-independent growth, and gap closure, reduced AKT phosphorylation, increased p27 abundance, and induced a senescence-associated phenotype. Basal SOX4 protein abundance decreased without a corresponding reduction in SOX4 mRNA, and proteasome inhibition restored SOX4 abundance. ACAT1 loss also prevented TNFα-induced SOX4 accumulation. Human prostate cancer specimens showed focal spatial overlap between ACAT1-positive regions and a subset of extranuclear SOX4 signals. ACAT1 loss induced broad metabolomic and lipidomic remodeling and neutral lipid accumulation without significantly altering palmitate oxidation. Extracellular lipid restriction attenuated lipid accumulation and alleviated the proliferative and AKT–p27 signaling defects. ACAT1 depletion increased PPARγ abundance, and the PPARγ antagonist GW9662 reduced lipid accumulation and alleviated these defects in ACAT1-knockout PC3 cells. Conclusions ACAT1 maintains basal and TNFα-induced SOX4 protein abundance and supports lipid homeostasis in ERG-negative prostate cancer cells. Its loss induces metabolic remodeling and extracellular lipid-dependent proliferative suppression. Rescue by lipid restriction and PPARγ antagonism supports a functional contribution of the lipid response to growth suppression.
No takes yet. Share an insight, caveat, or question.
Park et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: